The effect of fluoxetine on bone regeneration in rat calvarial bone defects.
OBJECTIVE
Fluoxetine is one of the most common medications used for the treatment of depression. Recent studies have demonstrated the possible effect of this drug on bone. The purpose of this study was to evaluate the effect of flouxetine on bone in Sprague-Dawley rats randomly divided into 3 groups (n = 7).


METHODS
Two calvarial defects, 5 mm diameter, were prepared in parietal bone. The left defects were filled with natural bovine bone mineral (NBBM) and the right defects were left untreated. The first group did not receive fluoxetine. The second group and the third group received 7.5 mg and 15 mg flouxetine, respectively, daily by gastric gavage. The animals were killed 8 weeks after surgery, and the amount of bone regeneration was evaluated using histometric analysis.


RESULTS
The defects showed dose-dependent increase in bone formation. The bone fill length had statistical significant differences between NBBM/flouxetine (15 mg) group and other groups (P < .05). The presence of the NBBM had positive effect on the bone formation in all groups in so far as the maximum amount of the increasing effect was seen in those rats filled with NBBM that received 15 mg flouxetine (P < .05). The minimum bone length in fluoxetine-treated defects was seen in 7.5 mg defects (0.36 mm)


CONCLUSIONS
Fluoxetine may improve the amount of bone regeneration in the rat calvarial defects.
Mortazavi
Seyed Hossein
SH
Department of Oral and Maxillofacial Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Khojasteh
Arash
A
Vaziri
Hamed
H
Khoshzaban
Ahad
A
Roudsari
Mohsen Vahid
MV
Razavi
Sayyed Hassan Emami
SH
D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001847:Bone Diseases / Q000473:pathology / Q000601:surgery*; D001857:Bone Matrix / Q000187:drug effects / Q000637:transplantation; D001861:Bone Regeneration / Q000187:drug effects; D018786:Bone Substitutes / Q000627:therapeutic use; D002417:Cattle; D003399:Craniotomy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008903:Minerals / Q000627:therapeutic use; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D010294:Parietal Bone / Q000187:drug effects* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
C077540:Bio-Oss; D050071:Bone Density Conservation Agents; D018786:Bone Substitutes; D008903:Minerals; D005473:Fluoxetine